



ASX Announcement

December 14, 2021

Change of Director's Interest Notices

Attached are Director's Interest Notices (Appendix 3Y) for Managing Director Jennifer Chow and Non-Executive Directors' Cindy Elkins and George Matcham, for the issue of unlisted options as approved by Shareholders at the Annual General Meeting held on 22 November 2021 to be issued within 30 days of shareholder approval.

Phillip Hains
Company Secretary

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

| | |
|------------------------|--|
| Name of Entity: | Chimeric Therapeutics Limited (ASX: CHM) |
| ABN: | 68 638 835 828 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|-----------------------------|------------------|
| Name of Director: | Jennifer Chow |
| Date of Last Notice: | 2 September 2021 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | | | | | | | | | | | | | | | |
|--|---|--------------|--|--|--------|---------|--------|--------------|--------------|----------|---|---|-------|-----------|-----------|
| Direct or Indirect Interest | Direct | | | | | | | | | | | | | | |
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | - | | | | | | | | | | | | | | |
| Date of change | 3 December 2021 | | | | | | | | | | | | | | |
| No. of securities held prior to change | <table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>670,498</td><td>8,291,495</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>670,498</td><td>8,291,495</td></tr></table> | | | | Shares | Options | Direct | 670,498 | 8,291,495 | Indirect | - | - | Total | 670,498 | 8,291,495 |
| | Shares | Options | | | | | | | | | | | | | |
| Direct | 670,498 | 8,291,495 | | | | | | | | | | | | | |
| Indirect | - | - | | | | | | | | | | | | | |
| Total | 670,498 | 8,291,495 | | | | | | | | | | | | | |
| Class | a) Fully Paid Ordinary Shares b) Unlisted Options. | | | | | | | | | | | | | | |
| Number acquired | <table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>a) 1,032,416</td><td>b) 2,000,000</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>1,032,416</td><td>2,000,000</td></tr></table> | | | | Shares | Options | Direct | a) 1,032,416 | b) 2,000,000 | Indirect | - | - | Total | 1,032,416 | 2,000,000 |
| | Shares | Options | | | | | | | | | | | | | |
| Direct | a) 1,032,416 | b) 2,000,000 | | | | | | | | | | | | | |
| Indirect | - | - | | | | | | | | | | | | | |
| Total | 1,032,416 | 2,000,000 | | | | | | | | | | | | | |
| Number disposed | <table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>-</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>-</td></tr></table> | | | | Shares | Options | Direct | - | - | Indirect | - | - | Total | - | - |
| | Shares | Options | | | | | | | | | | | | | |
| Direct | - | - | | | | | | | | | | | | | |
| Indirect | - | - | | | | | | | | | | | | | |
| Total | - | - | | | | | | | | | | | | | |

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

| | | | |
|--|--|------------------|-------------------|
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | a) \$0.272 per share b) Non-cash, see 'nature of change' below. | | |
| No. of securities held after change | | Shares | Options |
| | Direct | 1,702,914 | 10,291,495 |
| | Indirect | - | - |
| | Total | 1,702,914 | 10,291,495 |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | a) Issue of shares as part of sign-on payment for forfeiture of long-term incentive payment from previous employer as per section 9.8 of Prospectus lodged 18 January 2021. b) Issue of options as approved by Chimeric Therapeutics Limited shareholders at the Annual General Meeting held on 22 November 2021. | | |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|-----|
| Detail of contract | N/A |
| Nature of interest | N/A |
| Name of registered holder (if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| Interest after change | N/A |

+ See chapter 19 for defined terms.

Part 3 – Closed period

| | |
|--|-----|
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |



+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

| | |
|------------------------|--|
| Name of Entity: | Chimeric Therapeutics Limited (ASX: CHM) |
| ABN: | 68 638 835 828 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|-----------------------------|---------------|
| Name of Director: | Cindy Elkins |
| Date of Last Notice: | 10 March 2021 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | | | | | | | | | | | | | | | |
|--|---|-----------|--|--|--------|---------|--------|---|-----------|----------|--------|---|-------|--------|-----------|
| Direct or Indirect Interest | Direct | | | | | | | | | | | | | | |
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | - | | | | | | | | | | | | | | |
| Date of change | 3 December 2021 | | | | | | | | | | | | | | |
| No. of securities held prior to change | <table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>-</td></tr><tr><td>Indirect</td><td>24,800</td><td>-</td></tr><tr><td>Total</td><td>24,800</td><td>-</td></tr></table> | | | | Shares | Options | Direct | - | - | Indirect | 24,800 | - | Total | 24,800 | - |
| | Shares | Options | | | | | | | | | | | | | |
| Direct | - | - | | | | | | | | | | | | | |
| Indirect | 24,800 | - | | | | | | | | | | | | | |
| Total | 24,800 | - | | | | | | | | | | | | | |
| Class | Unlisted Options. | | | | | | | | | | | | | | |
| Number acquired | <table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>2,750,000</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>2,750,000</td></tr></table> | | | | Shares | Options | Direct | - | 2,750,000 | Indirect | - | - | Total | - | 2,750,000 |
| | Shares | Options | | | | | | | | | | | | | |
| Direct | - | 2,750,000 | | | | | | | | | | | | | |
| Indirect | - | - | | | | | | | | | | | | | |
| Total | - | 2,750,000 | | | | | | | | | | | | | |
| Number disposed | <table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>-</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>-</td></tr></table> | | | | Shares | Options | Direct | - | - | Indirect | - | - | Total | - | - |
| | Shares | Options | | | | | | | | | | | | | |
| Direct | - | - | | | | | | | | | | | | | |
| Indirect | - | - | | | | | | | | | | | | | |
| Total | - | - | | | | | | | | | | | | | |

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

| | | | |
|--|--|---------------|------------------|
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | Non-cash, see 'nature of change' below. | | |
| No. of securities held after change | | Shares | Options |
| | Direct | - | 2,750,000 |
| | Indirect | 24,800 | - |
| | Total | 24,800 | 2,750,000 |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Issue of options as approved by Chimeric Therapeutics Limited shareholders at the Annual General Meeting held on 22 November 2021. | | |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|-----|
| Detail of contract | N/A |
| Nature of interest | N/A |
| Name of registered holder (if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| Interest after change | N/A |

Part 3 – Closed period

| | |
|--|-----|
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |



13 December 2021

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

| | |
|------------------------|--|
| Name of Entity: | Chimeric Therapeutics Limited (ASX: CHM) |
| ABN: | 68 638 835 828 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|-----------------------------|-------------------|
| Name of Director: | Dr George Matcham |
| Date of Last Notice: | 9 August 2021 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | | | |
|--|-------------------|----------------|------------------|
| Direct or Indirect Interest | Direct | | |
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | - | | |
| Date of change | 3 December 2021 | | |
| No. of securities held prior to change | | Shares | Options |
| | Direct | 500,000 | - |
| | Indirect | - | - |
| | Total | 500,000 | - |
| Class | Unlisted Options. | | |
| Number acquired | | Shares | Options |
| | Direct | - | 2,750,000 |
| | Indirect | - | - |
| | Total | - | 2,750,000 |
| Number disposed | | Shares | Options |
| | Direct | - | - |
| | Indirect | - | - |
| | Total | - | - |

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

| | | | |
|--|--|----------------|------------------|
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | Non-cash, see 'nature of change' below. | | |
| No. of securities held after change | | Shares | Options |
| | Direct | 500,000 | 2,750,000 |
| | Indirect | - | - |
| | Total | 500,000 | 2,750,000 |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Issue of options as approved by Chimeric Therapeutics Limited shareholders at the Annual General Meeting held on 22 November 2021. | | |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|-----|
| Detail of contract | N/A |
| Nature of interest | N/A |
| Name of registered holder (if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| Interest after change | N/A |

Part 3 – Closed period

| | |
|--|-----|
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |



+ See chapter 19 for defined terms.